Sobuzoxane (MST-16) is an approved anticancer agent, a pro-drug of bisdioxopiperazine analog ICRF-154. Due to the structural similarity of ICRF-154 to dexrazoxane (ICRF-187), MST-16 deserves attention as a cardioprotective drug. This study presents for the first time UHPLC-MS/MS assay of MST-16, ICRF-154 and its metabolite (EDTA-diamide) in cell culture medium, buffer, plasma and cardiac cells and provides data on MST-16 bioactivation under conditions relevant to investigation of cardioprotection of this drug. The analysis of these compounds that differ considerably in their lipophilicity was achieved on the Zorbax SB-Aq column using a mixture of aqueous ammonium formate and methanol as a mobile phase. The biological samples were either diluted or precipitated with methanol, which was followed by acidification for the assay of MST-16. The method was validated for determination of all compounds in the biological materials. The application of the method for analysis of samples from in vitro experiments provided important findings, namely, that (1) MST-16 is quickly decomposed in biological environments, (2) the cardiac cells actively metabolize MST-16, and (3) MST-16 readily penetrates into the cardiac cells and is converted into ICRF-154 and EDTA-diamide. These data are useful for the in-depth examination of the cardioprotective potential of this drug.

Faculty of Pharmacy in Hradec Králové Charles University Akademika Heyrovského 1203 500 05 Hradec Králové Czech Republic

Zobrazit více v PubMed

Lu DY, Lu TR. Antimetastatic activities and mechanisms of bisdioxopiperazine compounds. Anticancer Agents Med. Chem. 2010;10:564–570. doi: 10.2174/187152010793498654. PubMed DOI

Narita T, et al. Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models. Cancer Chemother. Pharmacol. 1990;26:193–197. doi: 10.1007/BF02897198. PubMed DOI

Lu DY, Lu TR. Anticancer activities and mechanisms of bisdioxopiperazine compounds probimane and MST-16. Anticancer Agents Med. Chem. 2010;10:78–91. doi: 10.2174/1871520611009010078. PubMed DOI

Swift LP, et al. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother. Pharmacol. 2008;61:739–749. doi: 10.1007/s00280-007-0528-2. PubMed DOI

Narita T, et al. Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine) Cancer Chemother. Pharmacol. 1991;28:235–240. PubMed

Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 1991;51:4903–4908. PubMed

Cvetkokic RS, Scott LJ. Dexrazoxane - A review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65:1005–1024. doi: 10.2165/00003495-200565070-00008. PubMed DOI

Sterba M, et al. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid. Redox Signal. 2013;18:899–929. doi: 10.1089/ars.2012.4795. PubMed DOI PMC

Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 1998;5:1–28. PubMed

Hasinoff BB, Schroeder PE, Patel D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol. Pharmacol. 2003;64:670–678. doi: 10.1124/mol.64.3.670. PubMed DOI

Lyu YL, et al. Topoisomerase II beta-Mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67:8839–8846. doi: 10.1158/0008-5472.CAN-07-1649. PubMed DOI

Deng S, et al. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer. 2014;14:842. doi: 10.1186/1471-2407-14-842. PubMed DOI PMC

Vejpongsa P, Yeh ET. Topoisomerase 2beta: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin. Pharmacol. Ther. 2014;95:45–52. doi: 10.1038/clpt.2013.201. PubMed DOI

Zhang S, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 2012;18:1639–1642. doi: 10.1038/nm.2919. PubMed DOI

Yoshida M, Maehara Y, Sugimachi K. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy. Clin. Cancer Res. 1999;5:4295–4300. PubMed

Vavrova A, et al. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS One. 2013;8:e76676. doi: 10.1371/journal.pone.0076676. PubMed DOI PMC

Li T, et al. A simple LC-MS/MS method for determination of deferasirox in human plasma: Troubleshooting of interference from ferric ion in method development and its application. J. Pharm. Biomed. Anal. 2018;151:145–150. doi: 10.1016/j.jpba.2017.12.052. PubMed DOI

W. Li, J. Z., F.L.S. Tse. Handbook of LC-MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations. (John Wiley and Sons, 2013).

Bures J, et al. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology. 2017;392:1–10. doi: 10.1016/j.tox.2017.09.012. PubMed DOI

Kovarikova P, et al. Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium. J. Pharm. Biomed. Anal. 2013;76:243–251. doi: 10.1016/j.jpba.2012.12.024. PubMed DOI

Kovarikova P, Stariat J, Klimes J, Hruskova K, Vavrova K. Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites–the cardioprotectant dexrazoxane as a model case. J. Chromatogr. A. 2011;1218:416–426. doi: 10.1016/j.chroma.2010.11.050. PubMed DOI

Song TS, et al. Development of a fast LC-MS/MS assay for the determination of deferiprone in human plasma and application to pharmacokinetics. Biomed. Chromatogr. 2012;26:1575–1581. doi: 10.1002/bmc.2734. PubMed DOI

Sestak V, et al. Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents. Oncotarget. 2015;6:42411–42428. doi: 10.18632/oncotarget.6389. PubMed DOI PMC

Pauwels S, et al. Possibilities and limitations of signal summing for an immunosuppressant LC-MS/MS method. Anal. Bioanal. Chem. 2015;407:6191–6199. doi: 10.1007/s00216-015-8799-7. PubMed DOI

Pauwels S, et al. Sensitive routine liquid chromatography-tandem mass spectrometry method for serum estradiol and estrone without derivatization. Anal. Bioanal. Chem. 2013;405:8569–8577. doi: 10.1007/s00216-013-7259-5. PubMed DOI

European Medicines Agency, Guideline on bioanalytical method validation. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf (2012). PubMed

Jirkovsky E, et al. Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart. J. Pharmacol. Exp. Ther. 2018;364:433–446. doi: 10.1124/jpet.117.244848. PubMed DOI

Hasinoff BB. Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J. Pharm. Sci. 1994;83:64–67. doi: 10.1002/jps.2600830115. PubMed DOI

Dawson KM. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem. Pharmacol. 1975;24:2249–2253. doi: 10.1016/0006-2952(75)90262-2. PubMed DOI

Schroeder PE, Wang GQ, Burczynski FJ, Hasinoff BB. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood. Drug Metab. Dispos. 2005;33:719–725. doi: 10.1124/dmd.104.003186. PubMed DOI

Stam H, Broekhoven-Schokker S, Schoonderwoerd K, Hulsmann WC. Cholesteryl esterase activities in ventricles, isolated heart cells and aorta of the rat. Lipids. 1987;22:108–115. doi: 10.1007/BF02534862. PubMed DOI

Hasinoff BB, Reinders FX, Clark V. The Enzymatic Hydrolysis-Activation of the Adriamycin Cardioprotective Agent (+)-1,2-Bis(3,5-Dioxopiperazinyl-1-Yl)Propane. Drug Metab. Dispos. 1991;19:74–80. PubMed

Schroeder PE, Davidson JN, Hasinoff BB. Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187) Drug Metab. Dispos. 2002;30:1431–1435. doi: 10.1124/dmd.30.12.1431. PubMed DOI

Dudley KH, Butler TC, Bius DL. The role of dihydropyrimidinase in the metabolism of some hydantoin and succinimide drugs. Drug Metab. Dispos. 1974;2:103–112. PubMed

Buss JL, Hasinoff BB. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) Arch. Biochem. Biophys. 1995;317:121–127. doi: 10.1006/abbi.1995.1143. PubMed DOI

Buss JL, Hasinoff BB. Metal ion-promoted hydrolysis of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and its one-ring open hydrolysis products to its metal-chelating active form. J. Inorg. Biochem. 1997;68:101–108. doi: 10.1016/S0162-0134(97)00080-9. DOI

Hasinoff BB, Aoyama RG. Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat. Drug Metab. Dispos. 1999;27:265–268. PubMed

National Research Council, Guide for the Care and Use of Laboratory Animals, https://olaw.nih.gov/sites/default/files/Guide-for-the-Care-and-Use-of-Laboratory-Animals.pdf (2011).

Simunek T, et al. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. Br. J. Pharmacol. 2008;155:138–148. doi: 10.1038/bjp.2008.236. PubMed DOI PMC

Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity